U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006532) titled 'Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab' on May 27.
Brief Summary: Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. Wh...